Reply to thread

Yes some good, but the very best of Immunex left with the deal.  Remaining folks good scientists yes, but output of antibodies against genes cloned at Immunex is from the foundational strength of Immunex (some of the best early cloners), and not a lot of productivity after that, but the blame lies with management, not the scientists.  Not sure the new crop of Immunex folks came up with good targets, but anyway, nobody came up with good drugs (outside of DMAB, old Amgen drug), and that is all that matters.  But yes, no way to recover an in-house discovery capacity, especially since it was devalued by Kevin since before he became CEO.